Training

Overview

Training scientists in vaccine research and development is crucial in order to sustain Europe’s excellence in this field. The TRANSVAC2 Consortium has set up training modules at leading European centres (in collaboration with WP18 partners) that can be combined to create customised international courses on vaccine R&D. Two rounds of customised training courses are planned. Participants can select topics as needed in their field of vaccine development, and the timelines of the various modules will be harmonised in a way that allows a logical continuation from one topic to the other.

Training modules

Date

15-18 October 2018 / October 2020

Duration

4 days

Deadline

1 July 2018 / 1 July 2020

# Participants

12

Organizer/Location

University of Oxford (UOXF)/Oxford, UK

Accommodation

Accommodation will be provided

Course objectives

1. To give an overview of vaccine biomanufacturing including considerations for taking pre-clinical vaccine candidates into GMP manufacture, the principles of GMP (good manufacturing practice), and an overview of small to large scale manufacture.

2. To provide an overview of vaccine clinical development including examples from experimental and licensed vaccines; to impart the importance of clinical trial design, immunomonitoring, statistical considerations and ethical considerations.

Course content

A list of the course contents is given on the website, link below. It includes a visit to a small-scale biomanufacturing facility.

Learning Outcomes

A. To gain an understanding of the vaccine development process, including GMP manufacture and testing vaccine safety and efficacy in clinical trials.

B To be able to apply the understanding to vaccines being designed, manufactured and developed by the participant

Who should apply

Anyone working in vaccinology, or interested in learning about the vaccine clinical development process, including those from academia, industry, or regulatory bodies

Minimal requirements

None, but ideally a background in biological science and/or first degree in related subject

Contact

Rebecca Ashfield (rebecca.ashfield@ndm.ox.ac.uk)

Weblink

https://www.conted.ox.ac.uk/courses/clinical-vaccine-development-and-biomanufacturing?code=O17C001C9Y

Date

19-23 November 2018 / November 2020

Duration

5 days

Deadline

1 July 2018 / 1 July 2020

# Participants

12

Organizer/Location

University of Oxford (UOXF), Oxford,UK

Accommodation

Accommodation will be provided

Course objectives

The course covers both human and veterinary vaccinology, highlighting important principles which are relevant to vaccine deployment for human and animal diseases, and the One Health approach. Using a number of examples, it explores vaccine design and efficacy testing, and the use of adjuvants.

Course content

A list of the course contents is given on the website, link below.

Learning Outcomes

A. To gain an understanding of the principles of vaccinology, including vaccine design, efficacy testing and deployment in the field.

B. To gain the ability to apply the knowledge to design new vaccines, for either human or veterinary diseases.

Who should apply

Anyone working in vaccinology, or interested in learning about the vaccine design and development.

Minimal requirements

None, but ideally a background in biological science and/or first degree in related subject

Contact

Rebecca Ashfield (rebecca.ashfield@ndm.ox.ac.uk)

Weblink

https://www.conted.ox.ac.uk/courses/human-and-veterinary-vaccinology?code=O17C002C9Y

Date

25 - 28 March 2019 / March 2021

Duration

4 days

Deadline

1 November 2018 / 1 November 2020

# Participants

10

Organizer/Location

Vaccine Formulation Institute (VFI) / Geneva, Switzerland

Accommodation

Accommodation will be provided

Course objectives

The course provides an overview of State-of-the-art adjuvant systems and addresses the preclinical and clinical development of adjuvanted vaccines.

Course content

Combination of lectures, discussion rounds, and group work on thematic case studies. Topics: Adjuvant systems, such as aluminum salts, oil-in-water emulsions, water-in-Oil emulsions, liposomes, PLGA particles, virosomes, QS21, TLR ligands) and preclinical and clinical development of adjuvanted vaccines

Learning Outcomes

Good understanding of the different adjuvant systems and of the challenges of preclinical and clinical development of adjuvanted vaccines.

Who should apply

Scientists and professionals involved in research and development of vaccines who are working with – or planning to work with – adjuvants.

Minimal requirements

Applicants should have a BSc or MSc, or have demonstrable vaccine-related research experience.

Comments

The course will be organized in collaboration with ENOVA, the European Network of Vaccine Adjuvants. ENOVA will sponsor 10 additional participants, selected via the separate ENOVA call for applications.

Contact

Maria Lawrenz (maria.lawrenz@vformulation.org)

Date

Q2 2019 / Q2 2021

Duration

2 days

Deadline

1 February 2019 / 1 February 2021

# Participants

up to 30 participants

Organizer/Location

Wageningen University (SWR) / Lelystad, The Netherlands

Accommodation

Accommodation is not covered, to be arranged by participants

Course objectives

TBA

Course content

Course will critically discuss the use of animal models in vaccine development

Learning Outcomes

TBA

Who should apply

TBA

Minimal requirements

TBA

Contact

Norbert Stockhofe (norbert.stockhofe@wur.nl)

 

Date

Q2 2019 / Q2 2021

Duration

5 days

Deadline

1 February 2019 / 1 February 2021

# Participants

max. 10

Organizer/Location

BPRC/Rijswijk, The Netherlands

Accommodation

Accommodation is not covered, to be arranged by participants (with help from BPRC).

Two hotels close to BPRC:

– https://www.bestwestern.nl/hotels/best-western-plus-grand-winston-rijswijk-92737

https://www.bastionhotels.com/nl-nl/hotels/hotel-rijswijk

Course objectives

Increase proficiency in (vaccine) study design and analysis

Course content

ARRIVE guidelines, experimental design and power calculations, randomisation and blinding, data management and audit trail, hands on analysis of data from vaccine studies, data reporting (Tables and Figures)

Learning Outcomes

Capacity to design and analyse vaccine studies

Who should apply

PhD students and postdocs performing (pre) clinical vaccine studies

Minimal requirements

Basic knowledge of statistics (Statistics at Square One) and experience with Excel and R statistics software (RDebuts by E. Paradis). Books will be supplied.

Comments

Participants should bring their own computer with R software installed

Contact

Ed Remarque (remarque@bprc.nl)

 

Date

Q3 2019 / Q3 2021

Duration

3 days

Deadline

1 May 2019 / 1 May 2021

# Participants

12

Organizer/Location

CEA/18 route du Panorama, 92265, Fontenay-aux-Roses, France

Accommodation

Accommodation is not covered, to be arranged by participants. Hotel suggestions: 

CAMPANILE, 360 avenue du Général Leclerc, 92140 Clamart

LA Roseraie, 32 Avenue Jeanne et Maurice Dolivet, 92260 Fontenay-aux-Roses

Grand Hotel, 51 avenue Aristide Briand, 92350 Le Plessis Robinson

Course objectives

TBA

Course content

This three-day module will be organised in collaboration with the FlowCyTech core facility at CEA and will comprise lectures from experts in the field, practical work, demonstrations and open discussions.

Learning Outcomes

To be introduced to mass cytometry from the basic theory to data analysis and biological interpretation of the results.

Who should apply

Anyone with the minimal requirements and wishing to be introduced to mass cytometry

Minimal requirements

Basic flow cytometry knowledge (3 to 4 colour experiments)

Comments

https://www.ncbi.nlm.nih.gov/pubmed/29023707

Contact

Antonio Cosma (antonio.cosma@cea.fr)

Weblink

http://www.idmitcenter.fr/technologies/flowcytech/

Date

Q3 2019 / Q3 2021

Duration

3 days

Deadline

1 May 2019 / 1 May 2021

# Participants

12

Organizer/Location

CEA/18 route du Panorama, 92265, Fontenay-aux-Roses, France

Accommodation

Accommodation is not covered, to be arranged by participants. Hotel suggestions: 

CAMPANILE, 360 avenue du Général Leclerc, 92140 Clamart

LA Roseraie, 32 Avenue Jeanne et Maurice Dolivet, 92260 Fontenay-aux-Roses

Grand Hotel, 51 avenue Aristide Briand, 92350 Le Plessis Robinson

Course objectives

TBA

Course content

This course will be organised in collaboration with the FlowCyTech core facility at CEA and will comprise lectures from experts in the field, practical work, demonstrations and open discussions using pre-submitted participant data.

Learning Outcomes

To master multi-dimensional flow cytometry from the basic theory to data analysis, and biological interpretation of the results.

Who should apply

Anyone with the minimal requirements and wishing to improve flow knowledge

Minimal requirements

Basic flow cytometry knowledge (3 to 4 colour experiments)

Comments

https://www.ncbi.nlm.nih.gov/pubmed/29023707

Contact

Antonio Cosma (antonio.cosma@cea.fr)

Weblink

http://www.idmitcenter.fr/technologies/flowcytech/

Date

Q3 2019 / Q3 2021

Duration

3 days

Deadline

1 May 2019 / 1 May 2021

# Participants

12

Organizer/Location

CEA/18 route du Panorama, 92265, Fontenay-aux-Roses, France

Accommodation

Accommodation is not covered, to be arranged by participants

Course objectives

TBA

Course content

Course will comprise lectures from experts in the field, practical work, demonstrations and open discussions

Learning Outcomes

TBA

Who should apply

TBA

Minimal requirements

TBA

Contact

Catherine Chapon (catherine.chapon@cea.fr)

 

Date

September 2019 / September 2021

Duration

2 days

Deadline

1 May 2019 / 1 May 2021

# Participants

10

Organizer/Location

Vaccine Formulation Insitute (VFI) in collaboration with Merck/M Lab, Molsheim, France

Accommodation

Accommodation will be provided.

Course objectives

Process development and scale-up of viral vaccines

Course content

Using a combination of theory and hands-on instruction, participants will learn the following: 

  • Key best practices and methods for vaccine process development from upstream to downstream focusing on a viral vaccine platform. 
    • Best practices of cell culturing in single use bioreactors for both adherent and suspension cells.
    • Optimization of filtration and purification technologies
    • Adjuvant filtration
  • How to integrate vaccine processes in a single use environment 

Learning Outcomes

Understand challenges and integrate key considerations for optimal viral vaccine process development and transition to manufacturing Learn how to implement a single use technology based process for viral vaccines

Who should apply

This course is designed for R&D scientists and engineers who are or will be responsible for developing and implementing production scale viral vaccine processes.

Minimal requirements

Prior experience with laboratory scale vaccine and/or biologics process development.

Contact

Anissa Boumlic (anissa.boumlic@merckgroup.com) and Maria Lawrenz (maria.lawrenz@vformulation.org)

 

Date

10-11 October 2019 / 7-8 October 2021

Duration

2 days

Deadline

1 July 2019 / 1 July 2021

# Participants

Max. 10

Organizer/Location

Fraunhofer IME, Aachen Germany

Accommodation

Accommodation will be provided

Course objectives

SPR-based assay development and validation

Course content

General overview on SPR-based analytics and application examples, practical example calibration free concentration analysis. Theoretical considerations regarding assay development and validation.

Learning Outcomes

Comprehensive insight into the possibilities to develop and implement SPR-based assays in vaccine research, R&D and quality control.

Who should apply

Scientists involved or interested in vaccine R&D and manufacturing projects.

Minimal requirements

Bachelor or Master’s degree in Biological or Biophysical Science, general interest in Biomolecular Interaction Studies, some experience with biological assays

Contact

Holger Spiegel (holger.spiegel@ime.fraunhofer.de)

 

Date

7-8 October 2019 / 4-5 October 2021-M11

Duration

2 days

Deadline

1 July 2019 / 1 July 2021

# Participants

Max. 15

Organizer/Location

Fraunhofer IME, Aachen Germany

Accommodation

Accommodation will be provided

Course objectives

Process development and scale-up of recombinant protein vaccines.

Course content

General strategies in process development for recombinant protein production and purification in different host systems with a special focus  on state of the art methods to improve down-stream process development by implementing design of experiments and quality by design aspects, e.g. in clarification and chromatographic purification. Typical processes will be discussed using real-life equipment and examples.

Learning Outcomes

Comprehensive insight into the possibilities to conduct and improve process development and scale-up of biomanufacturing processes.

Who should apply

Scientists involved or interested in vaccine R&D and manufacturing projects.

Minimal requirements

Basic understanding of recombinant DNA technology, protein chemistry and typical process unit operations.

Contact

Johannes Buyel (johannes.buyel@ime.fraunhofer.de)

 

Date

Q4 2019 / Q4 2021

Duration

2 days

Deadline

1 July 2019 / 1 July 2021

# Participants

Max. 15

Organizer/Location

Fraunhofer IME, Aachen Germany

Accommodation

Accommodation will be provided

Course objectives

Requirements for GMP production

Course content

Requirements for GMP-production of vaccines or other drug substances regarding technical, analytical and regulatory aspects.

Learning Outcomes

Deeper insight into the requirements for GMP-production of vaccines or other drug substances.

Who should apply

Scientists involved or interested in vaccine R&D and manufacturing projects.

Minimal requirements

TBA

Contact

Jürgen Drossard (juergen.drossard@ime.fraunhofer.de)

 

Date

Q1 2020 / Q1 2022

Duration

3 days

Deadline

1 November 2019 / 1 November 2021

# Participants

15 participants

Organizer/Location

University of Siena/ Siena,Italy

Accommodation

TBC

Course objectives

TBA

Course content

TBA

Learning Outcomes

TBA

Who should apply

TBA

Minimal requirements

TBA

Contact

Donata Medaglini (donata.medaglini@unisi.it)

 

Date

April 2-3, 2020 / April 7-8, 2022

Duration

2 days

Deadline

1 February 2020 / 1 February 2022

# Participants

15

Organizer/Location

EATRIS/Amsterdam, the Netherlands

Accommodation

1 hotel night, 1 lunch and 1 dinner included

Course objectives

Regulatory vaccinology training module to increase preparedness of vaccine developers.

Course content

The course is designed for professionals working on vaccine development who are in need of an introduction to the regulatory issues associated with the field.

Learning Outcomes

Learn how to plan a regulatory strategy from the early phases of development and prepare a well-organised dossier in a changing environment.

Who should apply

Vaccine developers and European researchers from industry and academia.

Minimal requirements

TBA

Contact

Rosan Vegter (rosanvegter@eatris.eu)

 

Apply Now

How to apply

Format of the application

Applicants must use the application form available at the TRANSVAC2 website and submit it electronically in PDF format by e-mail to transvacinfo@euvaccine.eu. Any paper versions of applications will be rejected.

The responses submitted to this call for applications may not exceed the maximum number of pages indicated in the application form. Any sections of the application exceeding the maximum number of pages will be disregarded.

Confirmation of receipt

Receipt of your application will be acknowledged within two working days. Applications not acknowledged as received may have not been successfully transmitted and should be resubmitted via e-mail. Under no circumstances will TRANSVAC2 accept responsibility for lost e-mails or consider applications received after the deadline. Applicants are solely responsible for ensuring that their applications are received and acknowledged before the deadline.

Language

All applications must be written in English.

Submitting on time

Applications may be submitted on or after the opening date, and must be successfully received by the TRANSVAC2 management team no later than the submission deadline (5:00 p.m. CET/CEST on the application cut-off date). If an application is not received by the deadline, it will not be acknowledged and therefore not reviewed. See also: Confirmation of receipt (above).

The deadline for applications for Training Module 3 is 1 November 2018.

Selection process

Evaluation and Selection of Candidates

Each training module will have one Course Selection Panel (CSP) composed of three TRANSVAC WP18 members, (rolling membership), including one representative of the organizing institution. 

Participants will be selected by the Course Selection Panel (CSP), according to their educational background, involvement in vaccine research and development as well as the expected impact of the course at personal and institutional level in the context of vaccine development i.e. how the training can be used in their daily work.

Individual criteria for training modules are outlined in the description of the respective course.

The nominated candidates and outcomes of the training modules will be published on the TRANSVAC2 website.

Financial Assistance

Financial Assistance

There is no admission fee for any of the training courses.  However, short-listed candidates will have to cover their own travel and visa expenses, and for some courses they have to cover also accommodation costs. For more details please see the relevant training description.

Each organizing institution will administer and oversee the operation of its training module according to the agreed standards and procedures. For some courses, full-board accommodation will be provided free of charge.

Eligibility criteria

Candidates working in a European Union Member State or Associated Member State are eligible to apply. Candidates from another country who are working in vaccine development projects funded by the European Commission (EC) or EDCTP will also be eligible to apply. Other candidates can also apply, but preference will be given to the groups mentioned above.

Candidates must preferably already possess training in the area of vaccine research and development from an internationally recognized university or institution. Graduates with a Bachelor degree, a Master’s degree or comparable research experience will be strongly preferred.

Call Schedule

Call number TR1806-1 TR1810-2 TR1901-3 TR1904-4 TR1906-5 TR1910-6 TR2001-7
Training modules M1
M2
M3 M4
M5
M6
M7
M8
M9
M10
M11
M12
M13 M14
Launch of the call 1 Jun 18 1 Oct 18 1 Jan 19 1 Apr 19 1 Jun 19 1 Oct 19 1 Jan 20
Deadline for submission 1 Jul 18 1 Nov 18 1 Feb 19 1 May 19 1 Jul 19 1 Nov 19 1 Feb 20
Expected decision date 1 Aug 18 1 Dec 18 1 Mar 19 1 Jun 19 1 Aug 19 1 Dec 19 1 Mar 20

The calls for the second round are expected to follow the same schedule of the cut-off dates.

Module Schedule

Module Nr TRAINING Round I Round II
  2018 2019 2020   2021 2022
  Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
M1 Clinical vaccine development and biomanufacturing x               x                
M2 Human and Veterinary vaccine development x               x                
M3 Adjuvants and Vaccine Formulation   x               x              
M4 Validity and comparison of animal models     x               x            
M5 Statistics for Vaccine Evaluation     x               x            
M6 CyTOF       x               x          
M7 Flow cytometry       x               x          
M8 In vivo Imaging       x               x          
M9 Key considerations and best practices for viral vaccine process development, scale-up and implementation at manufacturing scale including single use technologies       x               x          
M10 Assay Development and Validation-Application of SPR Technologies in Vaccine development and manufacturing         x               x        
M11 Process development and scale-up of recombinant protein vaccines         x               x        
M12 Requirements for GMP production         x               x        
M13 Systems biology of vaccinology           x               x      
M14 Regulatory aspects of vaccine development             x               x    
  • Services

    Services

  • Who we are

    Who we are

  • Our training courses

    Training courses

  • Latest news

    Latest news